PIEZO1 Discovered as Key Driver of Dangerous Blood Vessel Malformations in HHT
A mechanosensitive ion channel fuels arteriovenous malformations in a hereditary bleeding disorder — and blocking it reduces AVM formation in mice.
Summary
Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder causing abnormal connections between arteries and veins, called arteriovenous malformations (AVMs), that can lead to life-threatening bleeding. Researchers at Yale discovered that PIEZO1 — a protein that senses physical forces like blood flow — is abnormally overactive in the diseased blood vessels of HHT patients and mouse models. When they genetically deleted or pharmacologically blocked PIEZO1, AVM formation was significantly reduced. Conversely, artificially activating PIEZO1 made AVMs worse. These findings reveal a new molecular target in HHT and suggest that PIEZO1 inhibitors, some already in development, could become new treatments for this currently hard-to-manage vascular disease.
Detailed Summary
Hereditary hemorrhagic telangiectasia type 2 (HHT2) is caused by loss-of-function mutations in ALK1 (Activin receptor-like kinase 1), a gene critical for normal blood vessel development. The condition leads to arteriovenous malformations — direct, abnormal shunts between arteries and veins that bypass capillary beds — causing recurrent nosebleeds, gastrointestinal hemorrhage, and potentially fatal pulmonary, hepatic, or cerebral AVMs. Despite understanding the genetic cause, the full molecular cascade linking ALK1 loss to AVM formation has remained incomplete, and current treatments are largely symptomatic or palliative. This study set out to map those missing links using advanced single-cell genomics and mouse genetics.
The research team performed single-cell RNA sequencing (scRNA-seq) on retinal endothelial cells from endothelial-specific Alk1 knockout (KO) mice and wild-type controls, a well-validated model of HHT2 vascular disease. Among the distinct cell clusters identified, one cluster of Alk1-mutant endothelial cells stood out dramatically: these cells showed simultaneously elevated signatures for fluid shear stress sensing, hypoxia, inflammation, cell cycle entry, and VEGFR2/PI3K/AKT signaling. Critically, this cluster also displayed strong upregulation of Piezo1, the gene encoding PIEZO1 — a mechanosensitive ion channel known to transduce blood flow forces in vascular endothelium. PIEZO1 overexpression was validated not only in Alk1 KO mouse retinas but also confirmed in AVM lesion tissue from human HHT2 patients, establishing clinical relevance.
To determine whether PIEZO1 upregulation is pathogenic rather than merely an epiphenomenon, the team performed genetic deletion of Piezo1 specifically in endothelial cells of Alk1 KO mice. Piezo1 deletion significantly mitigated AVM formation in the retinal model. Complementary pharmacological experiments using Dooku1, a selective PIEZO1 inhibitor, also markedly reduced AVM burden. In the reverse direction, forced Piezo1 overexpression in a separate model of HHT (induced by ALK1 ligand blockade using anti-BMP9/10 antibodies) dramatically enhanced AVM formation, establishing a causal relationship between elevated PIEZO1 activity and AVM pathogenesis.
Mechanistically, PIEZO1 inhibition in ALK1-deficient endothelium reduced multiple downstream pathways simultaneously: VEGFR2/AKT phosphorylation, ERK5-p62-KLF4 axis activation, endothelial nitric oxide synthase (eNOS) expression, hypoxia-inducible factor signaling, endothelial cell proliferation, and inflammatory marker expression. This multi-pathway suppression suggests PIEZO1 sits upstream of many of the known pathological mechanisms in HHT2, functioning as an integrating hub that amplifies disease when ALK1 is absent. The ERK5-p62-KLF4 axis is particularly notable, as KLF4 is a transcription factor associated with disturbed arterial flow and endothelial dysfunction.
The findings carry significant therapeutic implications. PIEZO1 is a druggable target, and small-molecule inhibitors are already under investigation for other indications. Unlike broad anti-VEGF approaches that may have systemic side effects, targeting PIEZO1 in the vascular endothelium offers a more mechanistically precise strategy. The confirmation of PIEZO1 overexpression in human HHT2 AVM specimens strengthens the translational potential. Caveats include the reliance on mouse retinal models, which may not fully recapitulate all aspects of human HHT pathophysiology, and the need for future studies to determine optimal dosing, safety, and efficacy of PIEZO1 blockade in more complex organ AVMs such as those in the lung or brain.
Key Findings
- Single-cell RNA sequencing of Alk1 KO mouse retinas identified a distinct endothelial cell cluster overexpressing Piezo1 alongside shear stress, hypoxia, inflammation, cell cycle, and VEGFR2/PI3K/AKT gene signatures simultaneously.
- Endothelial-specific genetic deletion of Piezo1 in Alk1 KO mice significantly reduced arteriovenous malformation formation in the retinal vascular model.
- Pharmacological inhibition of PIEZO1 using Dooku1 mirrored genetic deletion results, markedly reducing AVM burden in Alk1-deficient mice.
- Forced Piezo1 overexpression in a BMP9/10-ligand-blockade HHT model dramatically enhanced AVM formation, confirming a direct causal role for PIEZO1 in AVM pathogenesis.
- PIEZO1 inhibition reduced downstream VEGFR2/AKT phosphorylation, ERK5-p62-KLF4 axis activation, eNOS expression, hypoxia signaling, endothelial proliferation, and inflammatory markers in ALK1-deficient endothelium.
- PIEZO1 overexpression was confirmed in AVM lesion tissue from human HHT2 patients, validating the mouse model findings in human disease specimens.
- PIEZO1 appears to function as an upstream integrating hub that amplifies multiple established pathological pathways when ALK1 is lost, placing it as a convergence point for HHT2 pathogenesis.
Methodology
The study used endothelial-specific Alk1 knockout mice as a validated HHT2 model, with single-cell RNA sequencing of retinal endothelial cells from KO and wild-type controls to define transcriptomic alterations. Genetic rescue was achieved via endothelial-specific Piezo1 deletion in Alk1 KO mice, pharmacological inhibition was tested using Dooku1 (a selective PIEZO1 inhibitor), and gain-of-function was assessed via Piezo1 overexpression in an anti-BMP9/10 antibody-induced AVM model. Human validation used AVM lesion tissue from HHT2 patients under IRB-approved protocols at Yale University.
Study Limitations
The primary model system is the mouse retinal vasculature, which may not fully replicate the hemodynamic and anatomical complexity of human pulmonary, hepatic, or cerebral AVMs that cause the most serious HHT complications. The study does not provide pharmacokinetic or safety data for PIEZO1 inhibitors in the context of HHT, and long-term effects of endothelial PIEZO1 blockade on normal vascular physiology remain unexplored. No conflicts of interest were explicitly stated in the available manuscript text, though the work was supported by NIH and institutional funding.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: